19.02.2015 • NewsDede WillamsBotoxActavis

Actavis Changing Name to Allergan

Three months after acquiring US Botox producer Allergan for $66 billion, Ireland-based drugmaker Actavis has announced it will adopt Allergan as the name of the merged corporate entity as well as for its global branded pharmaceutical portfolio.

Shareholders will be asked to approve the change at the annual general meeting later this year. The name Actavis is planned to be retained for select geographic regions and product portfolios.

"By adopting the Allergan name for the corporation we will ensure that our corporate identity reflects the dramatic evolution of our company within the pharmaceutical industry," said Brent Saunders, CEO and President of Actavis.

"Uniting under the Allergan corporate umbrella, while retaining the Allergan and Actavis identities for the two respective businesses, defines to customers, competitors, employees and investors that this combination of two powerful, successful and growing companies is transformational, and will reflect our position as the most dynamic growth pharmaceutical company in global healthcare," Saunders added.

The takeover of the Botox maker in November 2014 followed a power struggle to gain control of the company, which had sought to shake off a hostile bid by Canadian pharmaceutical producer Valeant in cooperation with activist investor Bill Ackman's Pershing Square Capital Management.

Originally a New Jersey-based company, Actavis in 2013 relocated its headquarters to Ireland after agreeing to buy Irish drugmaker Warner Chilcott.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.